Contributing to the pharmaceutical field for neurological diseases has always been one of the priorities in research areas, particularly with the ageing population of the world resulting in an increase in Alzheimer's disease and emerging pathogens such as Covid-19. With the impenetrable Blood Brain Barrier, the brain is too inaccessible to therapeutics, leading us to apply new technologies such as immunosafe nanoparticles to cross BBB.
I am interested in this area of pharmacy, targeting brain tissue, releasing efficient cargo molecules, and reducing inflammation which are all essential for neural cell salvage.
Tehran University of Medical Sciences, Iran, Medical Doctorate
Islam Y, Ehtezazi P, Cashmore A, Marinsalda E, Leach AG, Coxon CR, Fatokun AA, Sexton DW, Khan I, Zouganelis G, Downing J, Pluchino S, Sivakumaran M, Teixido M, Ehtezazi T. 2020. The Inclusion of a Matrix Metalloproteinase-9 Responsive Sequence in Self-assembled Peptide-based Brain-Targeting Nanoparticles Improves the Efficiency of Nanoparticles Crossing the Blood-Brain Barrier at Elevated MMP-9 Levels Journal of Pharmaceutical Sciences, DOI Author Url
Noroozian M, Ehtezazi P, Seyedian M, Ghassemzadeh H, Nejat S. 2006. P3–059: A preliminary study on the validation of Persian Clock Test in Iran Alzheimer's & Dementia, 2 DOI